Navigation Links
Dendreon Announces Closing of Common Stock Offering
Date:5/13/2009

SEATTLE, May 13 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today the closing of its previously reported underwritten public offering of 10,700,000 shares of its common stock, which shares were offered for sale to the public at $19.20 per share. On May 8, 2009, Deutsche Bank Securities Inc., acting as sole manager of the offering, exercised in full its over-allotment option to purchase an additional 1,279,166 shares of common stock at the public offering price of $19.20 per share. The exercise of the option increased the size of the offering to an aggregate of 11,979,166 shares of common stock.

Dendreon received net proceeds from the offering of approximately $221 million, after deducting underwriting commissions and estimated offering expenses. Dendreon plans to use the net proceeds of the offering to develop manufacturing facilities, a distribution network, an information technology platform and other infrastructure, to hire sales and marketing, manufacturing, quality and other personnel in preparation for the licensure by the FDA and commercialization of PROVENGE(R) (sipuleucel-T), and for general corporate purposes, including working capital.

Copies of the prospectus supplement relating to the offering may be obtained by contacting: Deutsche Bank Securities Inc., Prospectus Department, Harborside Financial Center, 100 Plaza One, Jersey City, New Jersey 07311-3988, telephone: 1-800-503-4611.

Shelf registration statements relating to the sale of the securities were filed with the Securities and Exchange Commission and were effective on August 29, 2008 and May 7, 2009. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale woul
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SoundConnect , an award ... proud to announce the strategic additions of implementation, ... Boston, Charleston and Atlanta offices. SoundConnect’s organizational ... for hosted solutions, collaboration and mobility that improve ... , SoundConnect was founded in 2004, with the ...
(Date:7/29/2014)... number of significant technological challenges in their quest ... created for the James Webb Space Telescope. , ... a scientist at NASA,s Goddard Space Flight Center ... microshutter arrays that is, those activated by ... as the current technology,s magnetically activated arrays. This ...
(Date:7/29/2014)... 29, 2014   Sequenom, Inc. (NASDAQ: ... innovative genetic analysis solutions, and Mayo Medical Laboratories ... in the United States , have ... and applications. "We have great appreciation for ... and we welcome the opportunity to partner with the ...
(Date:7/29/2014)... Quantum Cheshire Cat: Can a particle be separated from ... Nature Communications , published the results of the first ... field, conducted by Chapman University in Orange, CA, and ... seen a cat without a grin," thought Alice in ... most curious thing I ever saw in my life!" ...
Breaking Biology Technology:SoundConnect Organization and Culture is Evolving 2Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4
... Enlarge and Worsen Over Time , , CHICAGO, June 15 ... enlarged leg veins as a cosmetic issue without recognizing they can ... their doctors for other health symptoms, Vein Clinics of America is ... from affecting their everyday routine. , , To view the ...
... 15 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... appointment of Scott Peterson, Ph.D., as Vice President, ... Dr. Peterson will be responsible for overseeing those ... will support the advancement of the Company,s pipeline ...
... June 15 Congressional Quarterly presents a 360-degree look ... follow-on versions of biotech drugs. This CQ Forum will ... groups, and leading researchers regarding the complex structures of ... Will the availability of these products save money for ...
Cached Biology Technology:Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 2Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 3Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 4Oncothyreon appoints Scott Peterson as Vice President of Research and Development 2Oncothyreon appoints Scott Peterson as Vice President of Research and Development 3
(Date:7/30/2014)... is a subject of major interest in neuroscience. ... during the distinct stages of Wallerian degeneration: transcription ... dedifferentiation. Although gene expression responses in the distal ... injury are known, differences in gene expression between ... Dengbing Yao and co-workers from Nantong University, China ...
(Date:7/30/2014)... multitude of cells types. Researchers would like to understand how ... cells that make up the organs and other structures of ... chains of sugars that dangle from proteins on surfaces of ... San Diego, has created synthetic molecules that can stand in ... to direct the process, they report in the Journal ...
(Date:7/30/2014)... scientists unveiled the first high-resolution map of the ... country of Per. The new and improved methodology ... change for future market-based carbon economies. The ... ecological diversity and it provides the critical input ... conservation, land use, and enforcement purposes. The technique ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... to John Ellis for his pioneering contributions to biochemistry, ... Professor in the Department of Biological Sciences at the ... of the Springer book How Science Works: Evolution. Dr. ... London, and completed postdoctoral studies at Oxford University. In ...
... centuries-old religious ceremony of an indigenous people in southern Mexico ... of fish, according to researchers from Texas A&M University. ... World, the Zoque people of southern Mexico would venture each ... Cueva del Azufre to implore their deities for a bountiful ...
... most frustrating problems faced by doctors who treat pancreatic cancer ... 38,000 people in the United States die of the disease ... For almost three decades, scientists and physicians have known ... virtually all pancreatic cancers, making it an important target for ...
Cached Biology News:Moved by religion: Mexican cavefish develop resistance to toxin 2Moved by religion: Mexican cavefish develop resistance to toxin 3UNC team discovers promising target for new pancreatic cancer treatments 2
... >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long been ... radiolabeled ligands selected to keep pace with ... of products and services for receptor research ... radioligands. If you do not find exactly ...
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
... optimized for siRNA applications, contains magnetic nanoparticles ... nucleic acid of interest. Exploiting magnetic force ... rapidly drawn towards and delivered into the ... Reagent can be used for adherent cells; ...
Biology Products: